Compare ARLO & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | IMTX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2018 | N/A |
| Metric | ARLO | IMTX |
|---|---|---|
| Price | $13.82 | $11.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $24.00 | $19.00 |
| AVG Volume (30 Days) | ★ 1.5M | 489.9K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.82 | $25.91 |
| P/E Ratio | $101.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.05 | $5.05 |
| 52 Week High | $19.94 | $12.41 |
| Indicator | ARLO | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 52.09 |
| Support Level | $13.78 | $9.05 |
| Resistance Level | $14.56 | $11.61 |
| Average True Range (ATR) | 0.55 | 0.60 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 98.25 | 63.10 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.